{"entity":{"id":"oh-do-youn","kind":"person","name":"Do-Youn Oh","aka":[],"tldr":"Principal investigator of TOPAZ-1, the trial that added immunotherapy to first-line chemotherapy for bile duct cancer.","summary":"Do-Youn Oh is Professor of Internal Medicine at Seoul National University Hospital, specialising in gastrointestinal and hepatobiliary oncology. She was principal investigator of TOPAZ-1, the trial that added the immunotherapy durvalumab to first-line gemcitabine plus cisplatin for advanced biliary tract cancer, the first phase 3 in more than a decade to improve outcomes in that disease. Her publications include the TOPAZ-1 report on durvalumab plus gemcitabine and cisplatin. She runs pancreatic and biliary clinical trials at Seoul National University Hospital, with interests in immunotherapy for biliary tract cancer and pancreatic cancer.","asOf":"2026-09-08","links":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oh%20DY%5BAuthor%5D%20biliary%20tract%20cancer%20Seoul%20National%20University"}],"tags":[],"related":[],"cancers":["cholangiocarcinoma","pancreatic"],"sections":[],"technologies":[],"targets":[],"drugs":["durvalumab","gemcitabine-cisplatin"],"companies":[],"institutions":["snuh"],"pathways":[],"terms":[],"trials":["topaz-1"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm-evidence"],"dependsOn":[],"notes":[],"role":"Professor of Internal Medicine; gastrointestinal and hepatobiliary oncology","institutionId":"snuh","specialisms":["Biliary tract cancer","Pancreatic cancer","Immunotherapy","Clinical trials"],"profiles":[{"label":"Seoul National University Hospital","url":"https://www.snuh.org"},{"label":"PubMed author search","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Oh%20DY%5BAuthor%5D%20biliary%20tract%20cancer%20Seoul%20National%20University"}],"papers":[{"title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1)","journal":"NEJM Evidence","year":2022,"doi":"10.1056/EVIDoa2200015"},{"title":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","journal":"The Lancet","year":2024,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet"}],"orcid":"0000-0003-1663-9901"},"route":"/people/oh-do-youn/","neighbours":{"cancer":[{"id":"cholangiocarcinoma","kind":"cancer","name":"Biliary tract cancer (cholangiocarcinoma)","route":"/cancers/cholangiocarcinoma/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"drug":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/"},{"id":"gemcitabine-cisplatin","kind":"drug","name":"Gemcitabine + cisplatin","route":"/drugs/gemcitabine-cisplatin/"}],"institution":[{"id":"snuh","kind":"institution","name":"Seoul National University Hospital","route":"/institutions/snuh/"}],"trial":[{"id":"topaz-1","kind":"trial","name":"TOPAZ-1","route":"/trials/topaz-1/"}],"journal":[{"id":"nejm-evidence","kind":"journal","name":"NEJM Evidence","route":"/journals/nejm-evidence/"}],"paper":[{"id":"paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026","kind":"paper","name":"Efficacy and safety of trastuzumab deruxtecan in patients with HER2-expressing biliary tract or pancreatic tumors: a subgroup analysis of DESTINY-PanTumor02","route":"/key-papers/paper-oh-destiny-pantumor02-biliary-pancreatic-esmo-open-2026/"},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/"},{"id":"paper-harding-lancet-oncol","kind":"paper","name":"Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study","route":"/key-papers/paper-harding-lancet-oncol/"}]}}